Abstract
Caregivers identify the need for continuous supervision of Alzheimer’s disease patients while awake as a “milestone” functional change that has a profound impact on the lives of the caregiver and patient. The specific predictors of this important functional change are not known. We determined specific cognitive, neuropsychiatric, and motor symptoms associated with Alzheimer’s disease patients needing supervision while awake in a longitudinal, ethnically diverse cohort of Alzheimer’s disease patients in Northern Manhattan. At the initial visit, neuropsychiatric and behavioral symptoms, including more hallucinations (OR=3.12) and lower elation (OR=0.13) were associated with the need for supervision while awake, as were poor memory (OR=0.89) and higher letter fluency (OR=1.33) abilities. The findings presented in the current study can aid clinicians and caregivers in prognosis and planning, suggest symptoms to target with non-pharmacological and pharmacological treatments to forestall this important functional “milestone”, and suggest priorities for future research.
Significance Statement
Need for supervision while awake is identified by caregivers of AD patients as a “milestone” symptom that greatly changes caregiving needs and quality of life
Specific neuropsychiatric and cognitive symptoms, including hallucinations, elation, and memory and executive dysfunction, are associated with a significantly increased or decreased need for supervision while awake
These patient-centered findings aid prognosis and planning, and indicate symptoms to prioritize for treatment and future research to improve AD patient functioning
Competing Interest Statement
Dr. Stern consults for Eisai, Lilly, and Arcadia. Columbia University licenses the Dependence Scale, and in accordance with university policy, Dr. Stern is entitled to royalties through this license. The remaining authors report no conflicts of interest.
Funding Statement
This study was supported by NIH/NIA (R01AG007370).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained and all study procedures were reviewed and approved by the New York State Psychiatric Institute Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- AD
- Alzheimer’s disease
- ADRD
- Alzheimer’s disease and related dementias
- MMSE
- Mini-Mental State Examination
- DS
- Dependence Scale (DS)
- CDR
- Clinical Dementia Rating Scale
- SRT
- Selective Reminding Test
